- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Florham Park Today
By the People, for the People
Celularity Receives Nasdaq Notice Over Late Annual Filing
Biotech firm working to complete and file overdue 10-K report as soon as possible.
Apr. 17, 2026 at 9:00pm
Got story updates? Submit your updates here. ›
The delayed filing of Celularity’s annual report reflects the operational challenges facing biotech firms as they navigate complex regulatory requirements.Florham Park TodayCelularity Inc., a regenerative medicine company, announced that it received a notice from Nasdaq stating the company is not in compliance with listing rules due to the delayed filing of its annual report on Form 10-K for the fiscal year ended December 31, 2025. The company is working to complete and file the report as soon as practicable, but there is no guarantee it will regain compliance within any exception period granted by Nasdaq.
Why it matters
Failure to file required financial reports on time can lead to delisting from the Nasdaq stock exchange, which would significantly impact a public company’s access to capital markets. Celularity’s delay highlights the challenges biotech firms can face in meeting regulatory deadlines, especially during periods of rapid growth and development.
The details
Celularity received the notice from Nasdaq on April 16, 2026, stating the company is not in compliance with the exchange’s listing rule requiring timely filing of periodic financial reports. The company has 60 days to submit a plan to regain compliance, and Nasdaq may grant an exception of up to 180 days from the original due date of the 10-K report for Celularity to file the document.
- Celularity received the Nasdaq notice on April 16, 2026.
- The company’s 10-K report for fiscal year 2025 was originally due to be filed by the end of March 2026.
The players
Celularity Inc.
A regenerative and cellular medicine company developing allogeneic and autologous cell therapies derived from the postpartum placenta.
Nasdaq
The Nasdaq Stock Market, one of the world’s leading stock exchanges, where Celularity’s shares are listed.
What’s next
The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.
The takeaway
This case highlights growing concerns in the community about repeat offenders released on bail, raising questions about bail reform, public safety on SF streets, and if any special laws to govern autonomous vehicles in residential and commercial areas.
